Browse by category

A study by researchers from the University of California San Diego has revealed compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking GLP-1 medications were less than half as likely to die within five years, compared to those who weren't on the drugs (15.5% versus 37

Implanting a silicone ring (MiniMizer Ring, Bariatric Solutions) and pouch resizing offer an effective therapeutic strategy for symptom control in patients with dumping syndrome (DS) and post-bariatric surgery hypoglycemia (PBH) independent of effects on glycaemic dynamics, according to the results of a prospective single-arm trial by researchers from the University of Freiburg, Freiburg, Germany. However, they cautioned that complete resolution of dumping symptoms is only po

Combining bariatric surgery with the weight loss medication liraglutide can help people who need to lose more weight post-metabolic bariatric surgery (MBS), Monash University and Alfred Health-led research has found. Wendy Brown "We have shown that for people who regain weight or don't have an optimal weight loss effect from bariatric surgery, adding in a weight loss drug will help them to lose weight, often at a lower dose than is needed in people who have not had surgery,"

In a major new study, researchers from Intermountain Health in Salt Lake City have found that GLP-1 receptor agonists used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events, and for those who have never had pancreatitis, being on a GLP1RA medication led to a four times lower risk of developing the condition. "Pancreatitis is incredibly painful and can be deadly. Once you have a patient with acute pancreatitis, you wan

A study led by the University of Barcelona has identified a key molecular mechanism in the loss of brown fat activity during ageing. The study opens up new perspectives for designing strategies to boost the activity of this tissue and prevent chronic metabolic and cardiovascular diseases as the population ages. From left to right, Tania Quesada-López, Francesc Villarroya, Albert Blasco-Roset, Marta Giralt, Alberto Mestres-Arenas, Joan Villarroya, Aleix Gavaldà-Navarro and Rub

Post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, has revealed that systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo). This reduction was seen regardless of BMI (less than versus greater than or equal to 35 kg/m2). In